PDCD1 and neoplasm: Although the expression of PD-1/PD-L1 is crucial during ICI treatment, targeting PD-1 with antibodies disrupts PD-1 signaling on all cells, not just tumor-specific T cells, which may induce an imbalance in the immune system and cause collateral damage.